FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Stock Information for Calyxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Calyxt Inc.

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Cellectis Provides Financial Results for the Second Quarter 2024
FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.